FBT - Biotech Is Worth The Hype But Do You Have The Data?
(Thank you for the bone crushing pic)
It’s finally here! No, not spring but the return of “Biotech Merger Mania — 2019 Edition!” At least that’s the theme that’s been hyped throughout the financial media over the last few days as speculation began to build around a possible buyout of tiny biotech Spark Therapeutics (ONCE) by Roche Holding (RHHBY) last week before being confirmed on Monday. The terms of the deal, with Roche paying a 122% premium to ONCE’s 2/22 closing price, were generous enough to make even the